New Patent Covering PROLOR's Reversible-Pegylation Platform Technology is Allowed by U.S. Patent Office

  New Patent Covering PROLOR's Reversible-Pegylation Platform Technology is
                        Allowed by U.S. Patent Office

PR Newswire

NES-ZIONA, Israel, Nov. 13, 2012

NES-ZIONA, Israel, Nov. 13, 2012 /PRNewswire/ --PROLOR Biotech, Inc. (NYSE
MKT: PBTH) today announced that the U.S. Patent and Trademark Office issued a
notice of allowance for a patent application covering the company's
long-acting reversible-pegylation technology (RPeg). Upon issuance, the new
patent will provide added intellectual property protection, including
additional compositions and configurations of long-acting drug product, in
addition to the already-issued U.S. patent covering the RPeg platform. PROLOR
licensed the RPEG technology platform from Yeda R&D Ltd., the commercial arm
of the Weizmann Institute of Science in Israel. The company expects this new
U.S. patent will be issued in the next few months.

PROLOR is using its RPeg technology to develop long-acting therapeutic
peptides and small molecules. RPeg's expected key competitive advantage is
its unique ability to enable development of long-acting drugs that target the
brain and must therefore be able to penetrate the blood-brain barrier. The
RPeg technology has been shown in animal models to significantly enhance the
half-life and improve the biological activity of a variety of peptides and
small molecules, including compounds that need to cross the blood-brain
barrier, such as the appetite suppressant peptide PYY, PROLOR's GLP-1/Glucagon
dual receptor agonist MOD-6030 in development for obesity and type 2 diabetes,
and the diabetes-related compound exendin-4, the blood pressure controlling
hormone ANP and the intravenous antibiotic drug gentamicin.

PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying
unique technologies, including patented CTP technology and its long-acting
reversible-pegylation technology, primarily to develop longer-acting
proprietary versions of already approved therapeutic proteins that currently
generate billions of dollars in annual global sales. The CTP technology is
applicable to virtually all proteins. PROLOR is developing a long-acting
version of human growth hormone, which successfully completed a Phase II
clinical trial. It also is developing long-acting versions of Factor VIIa and
Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide
for diabetes and obesity, all of which are in preclinical development. For
more information, visit

Safe Harbor Statement: This press release contains forward-looking
statements, which may be identified by words such as "expects," "plans,"
"projects," "will," "may," "anticipates," "believes," "should," "would",
"intends," "estimates," "suggests," "has the potential to" and other words of
similar meaning, including statements regarding the results of current
clinical studies and preclinical experiments and the effectiveness of PROLOR's
long-acting protein programs, which are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Investors
are cautioned that forward-looking statements involve risks and uncertainties
that may affect PROLOR's business and prospects, including the risks that
PROLOR may not succeed in generating any revenues or developing any commercial
products, including any long-acting versions of human growth hormone,
erythropoietin, interferon beta, GLP-1 and other products; that the
long-acting products in development may fail, may not achieve the expected
results or effectiveness and/or may not generate data that would support the
approval or marketing of these products for the indications being studied or
for other indications; that ongoing studies may not continue to show
substantial or any activity; that the actual dollar amount of any grants from
Israel's Office of the Chief Scientist is uncertain and is subject to policy
changes of the Israeli government, and that such grants may be insufficient to
assist with product development; and other risks and uncertainties that may
cause results to differ materially from those set forth in the forward-looking
statements. The results of clinical trials in humans may produce results that
differ significantly from the results of clinical and other trials in animals.
The results of early-stage trials may differ significantly from the results of
more developed, later-stage trials. The development of any products using the
CTP platform technology could also be affected by a number of other factors,
including unexpected safety, efficacy or manufacturing issues, additional time
requirements for data analyses and decision making, the impact of
pharmaceutical industry regulation, the impact of competitive products and
pricing and the impact of patents and other proprietary rights held by
competitors and other third parties. In addition to the risk factors
described above, investors should consider the economic, competitive,
governmental, technological and other factors discussed in PROLOR's filings
with the Securities and Exchange Commission. The forward-looking statements
contained in this press release speak only as of the date the statements were
made, and we do not undertake any obligation to update forward-looking
statements, except as required under applicable law.

Shai Novik, President           Barbara Lindheim
PROLOR Biotech, Inc.            BLL Partners, LLC
Tel: +1 866 644-7811            +1 212 584-2276


Press spacebar to pause and continue. Press esc to stop.